JP2016510213A5 - - Google Patents

Download PDF

Info

Publication number
JP2016510213A5
JP2016510213A5 JP2015551852A JP2015551852A JP2016510213A5 JP 2016510213 A5 JP2016510213 A5 JP 2016510213A5 JP 2015551852 A JP2015551852 A JP 2015551852A JP 2015551852 A JP2015551852 A JP 2015551852A JP 2016510213 A5 JP2016510213 A5 JP 2016510213A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
disease
iro compound
composition according
iro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015551852A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510213A (ja
JP6385957B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/010599 external-priority patent/WO2014110081A1/en
Publication of JP2016510213A publication Critical patent/JP2016510213A/ja
Publication of JP2016510213A5 publication Critical patent/JP2016510213A5/ja
Application granted granted Critical
Publication of JP6385957B2 publication Critical patent/JP6385957B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015551852A 2013-01-08 2014-01-08 トール様受容体に基づく免疫応答を調節するための免疫調節オリゴヌクレオチド（ｉｒｏ）化合物 Expired - Fee Related JP6385957B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361750014P 2013-01-08 2013-01-08
US61/750,014 2013-01-08
PCT/US2014/010599 WO2014110081A1 (en) 2013-01-08 2014-01-08 Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response

Publications (3)

Publication Number Publication Date
JP2016510213A JP2016510213A (ja) 2016-04-07
JP2016510213A5 true JP2016510213A5 (enExample) 2016-12-28
JP6385957B2 JP6385957B2 (ja) 2018-09-05

Family

ID=51061112

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015551852A Expired - Fee Related JP6385957B2 (ja) 2013-01-08 2014-01-08 トール様受容体に基づく免疫応答を調節するための免疫調節オリゴヌクレオチド（ｉｒｏ）化合物

Country Status (9)

Country Link
US (3) US9260719B2 (enExample)
EP (1) EP2943251B1 (enExample)
JP (1) JP6385957B2 (enExample)
KR (1) KR101898177B1 (enExample)
AU (2) AU2014205544B2 (enExample)
BR (1) BR112015016420B1 (enExample)
CA (1) CA2896537C (enExample)
HK (1) HK1214191A1 (enExample)
WO (1) WO2014110081A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110081A1 (en) * 2013-01-08 2014-07-17 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
US9688993B2 (en) 2015-02-13 2017-06-27 Idera Pharmaceuticals, Inc. Toll-like receptor 9 antagonist and methods of use thereof
EP3436066A1 (en) 2016-04-01 2019-02-06 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
EP3468605A4 (en) 2016-06-08 2020-01-08 President and Fellows of Harvard College MANIPULATED VIRAL VECTOR TO REDUCE INDUCTION OF IGNITION AND IMMUNE REACTIONS
AU2017364964B2 (en) * 2016-11-23 2023-04-20 Berlin Cures GmbH Aptamers for use in inhibition and/or suppression of TLR9 activation
JP2021502381A (ja) 2017-11-08 2021-01-28 プレジデント アンド フェローズ オブ ハーバード カレッジ ウイルスベクター誘発性炎症反応を阻害するための組成物および方法
EP3752194A4 (en) 2018-02-13 2022-03-16 Checkmate Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY
EP3775218A1 (en) 2018-04-09 2021-02-17 Checkmate Pharmaceuticals Packaging oligonucleotides into virus-like particles

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
AU9475001A (en) * 2000-09-26 2002-04-08 Hybridon Inc Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
US7176296B2 (en) * 2001-04-30 2007-02-13 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7105495B2 (en) * 2001-04-30 2006-09-12 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
WO2003035836A2 (en) * 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
CA2512484A1 (en) * 2003-01-16 2004-05-08 Hybridon, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
US7354907B2 (en) * 2003-02-07 2008-04-08 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
EP2371834B1 (en) * 2003-06-11 2016-02-17 Idera Pharmaceuticals, Inc. Stabilized immunomodulatory oligonucleotides
KR101126030B1 (ko) * 2003-07-15 2012-03-19 이데라 파마슈티칼즈, 인코포레이티드 사이토킨 및/또는 화학치료제 또는 방사선 치료와 연계하여면역자극 올리고누클레오티드 및/또는 이뮤노머 화합물을이용하여 면역계를 공동 상승 자극시키는 방법
US20050239733A1 (en) 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
HUE036894T2 (hu) * 2004-06-15 2018-08-28 Idera Pharmaceuticals Inc Immunstimuláló oligonukleotid multimerek
US7427405B2 (en) * 2004-06-15 2008-09-23 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
US8383598B2 (en) 2005-10-12 2013-02-26 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US8426375B2 (en) 2005-10-12 2013-04-23 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US8399423B2 (en) 2005-10-12 2013-03-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
ES2542989T3 (es) * 2005-10-12 2015-08-13 Idera Pharmaceuticals, Inc. Compuestos oligonucleótidos inmuno reguladores (IRO) para modular la respuesta inmune basada en receptor semejante a Toll
US7776834B2 (en) * 2005-11-07 2010-08-17 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
US7470674B2 (en) * 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
US7709317B2 (en) * 2005-11-14 2010-05-04 International Business Machines Corporation Method to increase strain enhancement with spacerless FET and dual liner process
CA2632940A1 (en) * 2005-12-20 2007-07-05 Idera Pharmaceuticals, Inc. Immunostimulatory activity of palindromic immune modulatory oligonucleotides (imo tm) contiaining different lengths of palindromic segments
KR20120115412A (ko) * 2006-04-07 2012-10-17 이데라 파마슈티칼즈, 인코포레이티드 Ｔｌｒ７ 및 ｔｌｒ８에 대한 안정화된 면역 조절성 ｒｎａ〔ｓｉｍｒａ〕 화합물
US8377898B2 (en) 2006-10-12 2013-02-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
WO2008073959A2 (en) * 2006-12-12 2008-06-19 Idera Pharmaceuticals, Inc. Synthetic agonists of tlr9
US8713253B1 (en) * 2007-06-18 2014-04-29 Guidance-Tableau, Llc Modular storage system
CA2692161C (en) * 2007-07-09 2015-09-29 Idera Pharmaceuticals, Inc. Stabilized immune modulatory rna (simra) compounds
CA2693266C (en) * 2007-08-01 2015-06-30 Idera Pharmaceuticals, Inc. Novel synthetic agonists of tlr9
US8853375B2 (en) * 2007-08-15 2014-10-07 Idera Pharmaceuticals, Inc. Toll like receptor modulators
WO2009154609A1 (en) * 2008-06-17 2009-12-23 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
KR20110071108A (ko) 2008-10-06 2011-06-28 이데라 파마슈티칼즈, 인코포레이티드 고콜레스테롤혈증 및 고지혈증 및 이에 관련된 질병의 예방 및 치료에서 톨-유사 수용체의 저해제의 용도
US8987221B2 (en) * 2009-06-01 2015-03-24 Idera Pharmaceuticals, Inc. Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (IRO) antagonists of TLR7 and TLR9
US9415046B2 (en) 2009-09-29 2016-08-16 Yale University Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods
BR112012032240A2 (pt) * 2010-06-16 2019-09-24 Dynavax Technologies Corporation método de tratamento utilizando inibidores tlr7 e/ou tlr9
US8486908B2 (en) * 2010-11-19 2013-07-16 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
WO2012167046A1 (en) * 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
US20140378537A1 (en) * 2011-09-09 2014-12-25 Genentech, Inc. Treatment of th17 mediated inflammatory diseases
EP3939572B1 (en) * 2012-04-12 2024-03-27 Yale University Vehicles for controlled delivery of different pharmaceutical agents
WO2014110081A1 (en) * 2013-01-08 2014-07-17 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
CN110096855B (zh) * 2013-05-30 2023-08-15 英特尔公司 自适应认证系统和方法
US9688993B2 (en) * 2015-02-13 2017-06-27 Idera Pharmaceuticals, Inc. Toll-like receptor 9 antagonist and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2016510213A5 (enExample)
JP2013544816A5 (enExample)
Velkov et al. Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead
ES2967453T3 (es) Compuestos de pirrolizina sustituidos y usos de los mismos
JP2010536787A5 (enExample)
Gane Future anti‐HBV strategies
TR201906470T4 (tr) İmmünomodülatörler.
JP2015513897A5 (enExample)
JP2015517489A5 (enExample)
JP2008056679A5 (enExample)
JP2006524669A5 (enExample)
JP2016538885A5 (enExample)
EP4378487A3 (en) Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
PH12017500797A1 (en) Substituted chromanes and methods of use
JP2019501133A5 (enExample)
JP2017531002A5 (enExample)
JP2009533348A5 (enExample)
MX2011007364A (es) Derivados de fosforamidato de compuestos de nuecleosido de guanosina para tratamiento de infecciones virales.
ES2897599T3 (es) Mejora de la administración de genes a células asesinas naturales, células madre hematopoyéticas y macrófagos
JP2017526728A5 (enExample)
Zhang et al. The response to interferon is influenced by hepatitis B virus genotype in vitro and in vivo
PH12014500724A1 (en) Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication
JP2015505843A5 (enExample)
JP2019506862A5 (enExample)
JP2016517446A5 (enExample)